Few are better qualified to make a difference, as long as they are allowed to

Pharmacy Guild of Australia President Professor Trent Twomey has welcomed the establishment of a new Masters of Pharmacy qualification.

Amgen has welcomed Health Minister Mark Butler's confirmation that the PBS listing of osteoporosis therapy EVENITY (romosozumab) has been expanded to a first-line setting for people who have had one fracture and are at very high risk of another.

The Albanese Government's Health Technology Assessment Review implementation group faces one early test: Will its members accept the same operating framework that dominated the review's reference group?

GBMA chair Professor Jane Halton AO PSM said economic modelling shows that each biosimilar molecule listed on the PBS could return up to $100 million to the health budget.

Moderna has announced that Dr Felicia Pradera will succeed Dr Craig Rayner as the director of its Regional Research Centre for Respiratory Medicines and Tropical Diseases.

Australian nuclear medicine company Telix Pharmaceuticals has expanded its theranostic pipeline with new assets targeting Fibroblast Activation Protein.

Today’s National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra will bring together more than 100 of Australia’s leading industry figures, policy experts, and innovators with the aim of shaping the future of the nation’s biotech and medtech sectors.

Bristol Myers Squibb Australia is hosting the third annual 'Patient and Parliament Summit' in Canberra today and tomorrow.

Moderna Australia has announced that the TGA has authorised its updated COVID-19 vaccine, SPIKEVAX JN.1, targeting the JN.1 variant of SARS-CoV-2 for people aged 12 and over.

Australian company AdAlta (ASX:1AD) has announced the appointment of two new directors, including former industry executive and current PBAC member Michelle Burke.

Newly-released documents reveal the genesis of lengthy prescribing restrictions, spending caps for new PBS listings, the Community Service Obligation, and a secret government process that led to an era of significant reforms.

The US-based research-based biopharmaceutical has acknowledged the appointment of Robert F Kennedy Jr to lead the Department of Health and Human Services.

Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, NUZ-001.

“It’s time to reorient the mindset around Pharmaceutical Benefits Scheme reimbursement. Australians with a clear medical need should not miss out on access to an innovative medicine with proven clinical benefit because the patient pool is considered too large to allow for Government funding,” said Eli Lilly general manager Tori Brown.

It is hard to argue that the avoidance of public criticism approach has been working, given the plethora of recent incidents of governments making decisions taken in secret, with the industry and other stakeholders subsequently informed as part of a Potemkin village consultation process.

Australian clinical-stage company Immutep has announced positive data from the INSIGHT-003 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.

If you criticise the fact of deferrals, but not the underhanded conduct, and accept the decision, what message does it send? If you state a preference for no non-dislosure agreements, and then repeatedly acquisece to them, what message does it send? If you repeatedly overtly prioritise participation as an outcome, what message does it send?

Medicines Australia says its chief executive should be on the Health Technology Assessment Review implementation group as the association pushes for continuity with the review's reference committee.

AusBiotech has announced the creation of the Depaz Oration, an annual keynote to be introduced at its national conference in 2025 in memory of the late Dr Iris Depaz.